Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuropsychiatric systemic lupus erythematosus

Abstract

We report the case of a 30-year-old caucasian woman affected by SLE who developed neurological symptoms (prosopagnosia and visual-spatial agnosia) after nine years of disease. Brain MRI showed no abnormalities while a brain SPECT scan showed diffuse uptake defects and hypoperfusion areas in the right and left frontal-parietal regions. At that time the patient was on hydroxychloroquine (400 mg/day) and oral prednisolone (0.5 mg/kg/day) as maintenance therapy. One year later the patient showed worsening of Raynaud's phenomenon with digital dystrophic lesions and was therefore treated with an intravenous infusion of Iloprost (1.5 ng/kg/min per 6h/ day for 10 days consecutively), while baseline treatment remained unchanged. One month later the patient showed a dramatic improvement in her cognitive function and subsequent SPECT scans showed the gradual disappearance of perfusion abnormalities. This first report of Iloprost treatment in CNS lupus suggests the potential therapeutic usefulness of this drug in patients with SLE and functional CNS involvement.

Keywords

SLE CNS cognitive disorders Iloprost therapy brain SPECT

Get full access to this article

View all access options for this article.

References

Hanly JG , Fisk JD , Sherwood G , Jones E , Jones JV , Eastwood B . Cognitive impairment in patients with systemic lupus erythematosus . J Rheumatol 1992; 19: 562–!567 .

Bruyn GA . Controversies in lupus: nervous system involvement . Ann Rheum Dis 1995; 54: 159–167 .

Rubbert A , Marienhagen J , Pimer K et al. Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus .Arthritis Rheum 1993; 36: 1253–1262 .

Sabbadini MG , Manfredi AA , Bozzolo E et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations . Lupus 1999; 8: 11–19 .

Sanna G , Piga M , Terryberry JW et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations . Lupus 2000; 9: 573–583 .

Harbeck RJ , Hoffman AA , Hoffman SA , Shucard DW . Cerebrospinal fluid and the choroid plexus during acute immune complex disease . Clin Immunol Immunopathol 1979; 13: 413–425 .

Kurki P , Helve T , Dahl D , Virtanen I . Neurofilament antibodies in systemic lupus erythematosus . J Rheumatol 1986; 13: 69–73 .

Denburg SD , Carbotte RM , Long AA , Denburg JA . Neuropsychological correlates of serum lymphocytotoxic antibodies in systemic lupus erythematosus . Brain Behav Immunol 1988; 2: 222–234 .

Alcocer-Varela J , Aleman-Hoey D , Alarcon-Segovia D . Interleukin-1and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers . Lupus 1992; 1: 111–117 .

10.

Asherson RA , Khamashta MA , Gil A et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus like disease, and the primary antiphospholipid syndrome . Am J Med 1989; 86: 391–399 .

11.

Fields RA , Sibbitt WL , Toubbeh H , Bankhurst AD . Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies . Ann Rheum Dis 1990; 49: 114–117 .

12.

Denburg JA , Denburg SD . Nervous system lupus: pathogenesis and rationale for therapy . Scand J Rheumatol 1995; 12: 263–273 .

13.

Mathieu A , Sanna G , Passiu G , Cauli A , Piga M . Raynaud's syndrome in systemic lupus erythematosus . Lancet 2000; 355: 1102–1103 .

14.

Krause W , Krais TH . Pharmacokinetics and pharmacodynamics of the prostacyclin analogue Iloprost in man . Eur J Clin Pharmac 1986; 30: 61–68 .

15.

Skuballa W , Raduchel B , Vorbruggen H . Chemistry of stable prostacyclin analogues: synthesis of iloprost. In: Gryglewski RG , Stock G (eds). Prostacyclin and its Stable Analogue Iloprost. Springer: Berlin , 1985, pp 17–24.

16.

Schror K , Davis H , Matzky R , Chlendorf R . The anti platelet and cardiovascular actions of a new carbocyclin (ZK36374) equipotent to PGI2 in vitro . Naunyn Schmiedebergs Arch Pharmac 1981; 316: 252–225 .

17.

Fisher CA , Kappa JR , Sinha AK , Cottrell ED , Reiser HJ , Addonizio VP . Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1 on human platelet function . J Lab Clin Med 1987; 109: 184–190 .

18.

Ferraccioli G , Di Poi E , Di Gregorio F , Giacomuzzi F , Guerra U . Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud's syndrome . Lancet 1999; 354: 2135–2136 .

19.

Olchewski H , Walmrath D , Schermuly R , Ghofrani A , Grimminger F , Seeger W . Aerosolized prostacyclin and Iloprost in severe pulmonary hypertension . Ann Intern Med 1996; 124: 820–824 .

20.

Egemen N , Baskaya MK , Turker RK et al. Protection by Iloprost (stable analogue of prostacyclin) of endothelial damage due to chronic vasospasm in dogs: an electron microscope study . Neurol Res 1995; 17: 301–306 .

21.

Keskil IS , Baykaner MK , Sencer H et al. Alteration by Iloprost of the vasospastic effects of endothelin-1 in rabbit cerebral vessels . Neuroreport 1994; 5: 1089–1092 .

22.

Wigley FM , Wise RA , Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study . Ann Intern Med 1994; 120: 199–206 .

23.

Biasi D , Carletto A , Caramaschi P et al. Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year . Rev Rheum Engl Ed 1998; 65: 745–750 .

24.

Pope J , Fenlon D , Thompson A et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000; CD000953-CD000953.

25.

Della Bella S , Molteni M , Mascagni B , Zulian C , Compasso S , Scorza R . Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine . Clin Exp Rheumatol 1997; 15: 135–141 .

26.

Mazzone A , Mazzucchelli I , Fossati G et al. Iloprost effects on phagocytes in patients suffering from ischaemic diseases: in vivo evidence for down-regulation of alpha M beta 2 integrin . Eur J Clin Invest 1996; 26: 860–866 .